<?xml version="1.0" encoding="utf-8" standalone="no"?>
<!DOCTYPE file
  SYSTEM 'wikixml.dtd'>
<file type="Article" date="2024-09-24T09:17:21Z" sourceCorpus="COVID-19" filename="68677280" title="Soberana_Plus" url="https://en.wikipedia.org/wiki/Soberana_Plus">
	<text>
		<segment id="id68677280">Soberana Plus, technical name FINLAY-FR-1A, is a COVID-19 candidate vaccine produced by the Finlay Institute, a Cuban epidemiological research institute.

Medical uses
It can be used as a third (booster) dose for Soberana 02 vaccine at eight weeks. It's also studied as an independent single-dose vaccine.

Efficacy
It combined the Soberana 02, the vaccine booster shot shows an efficacy of 91.2%. The final result of a third dose of Soberana Plus increased the efficacy up to 92.4%. Efficacy against severe disease and death is 100% for the heterologous three-dose regimen.

Clinical trials

Booster dose

Soberana Plus has also been studied as a booster dose for Soberana 02.

Single dose


Authorizations
On 20 August 2021, Cuba approved Soberana Plus as a booster after two doses of Soberana 02. On 23 September, Cuba approved Soberana Plus for COVID-19 survivors over 19 years old. On 7 December, the authorization was expanded to include COVID-19 survivors from 2 to 18 years old.

See also
* Soberana 02

References








</segment>
	</text>
</file>
